Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
Full Year Results 2024
Watch Riad Mishlawi, CEO

Latest stories
Featured
Hikma to host meet the management and site visit in Columbus, Ohio
Press Release, Corporate
17 March 2025
- Notice of results Press Release, Financial Results 09 July 2025 Notice of results
- Supporting communities globally: Highlights from our 2025 Global Volunteer Campaign Story, Responsibility 03 July 2025 Supporting communities globally: Highlights from our 2025 Global Volunteer Campaign
- Meet Farah Alasali, Senior Officer in our Social Responsibility team based in Jordan. Hear what she has to say about life at Hikma. #OwnYourCareer Story, Life at Hikma 02 July 2025 Meet Farah Alasali, Senior Officer in our Social Responsibility team based in Jordan. Hear what she has to say about life at Hikma. #OwnYourCareer
- Hikma receives FDA approval for TYZAVANTM (Vancomycin Injection, USP) in the US Press Release, Product 02 July 2025 Hikma receives FDA approval for TYZAVANTM (Vancomycin Injection, USP) in the US